Grace Breeding 2025: Maoz now has field proof, but the company still has not proved commercialization

Company Introduction

Grace Breeding is no longer just a lab story, but it is also still far from being a commercialization story. At the end of 2025 it was a tiny R&D company, with an equity value of about NIS 73.5 million based on a last price of 1,759 agorot and 4.18 million issued shares, holding 85% of its operating subsidiary Grace Technologies and concentrating almost all of its effort on one product, Maoz Bio 5, which is designed to allow up to 50% reduction in nitrogen fertilization in grain crops. A superficial reader could come away thinking the company is already sitting on a clean commercial move in Brazil. That is too early a read.

What is actually working now is the quality of the field proof. During 2025 Maoz Bio 5 became the company’s lead commercial version after successful field work. In Brazil, the company reported results showing that in certain applications it was possible to work with only 50% nitrogen without harming yield quantity or quality, and in one commercial observation it even recorded an 11% increase in yield. On top of that, GAPES, a group that brings together 44 corn growers cultivating around 290 thousand hectares, issued a formal recommendation to begin commercial use of the product in the next growing season. At the agronomic layer, Grace is therefore already well beyond the idea stage.

But the active bottleneck is not agronomy. It is commercialization and funding. The filing says plainly that the company does not yet sell Maoz, has no order backlog, and reported no revenue at all in the 2025 financial statements. At year-end it had NIS 474 thousand of cash, another NIS 101 thousand of short-term deposits, an equity deficit of NIS 203 thousand, and negative operating cash flow of NIS 1.789 million. The auditor emphasized that without additional funding the company would be able to continue its operations only for a few months after the approval date of the financial statements. That is the core of the story.

This gap matters because it changes how 2025 should be read. It was not a product-failure year, but it was also not a commercialization year. It was a year of field proof and balance-sheet survival. The product moved forward. The company itself still did not.

The proof map versus the friction

Events And Triggers

The central point is that 2025 brought Grace much stronger field proof, but not less friction on the way to market. Almost every positive trigger in the report comes with a practical constraint attached to it.

Maoz Bio 5 became the product, not just the experiment

Trigger one: the company says that out of the three Maoz versions, Maoz 5 was selected as the commercial lead after the 2025 field work. That matters because Grace is no longer trying to sell a broad story of several formulations. It is compressing the whole case into one product that is cheaper to handle, more stable, and applied at just 1 kilogram per hectare. Put differently, 2025 was a year of simplification.

Trigger two: in the GAIA trial in Brazil, which compared several application levels against the traditional 100% nitrogen treatment, Maoz Bio 5 delivered a 14% yield increase when used alongside 100% nitrogen and a 12% increase even when used with only 50% nitrogen. Beyond that, the company states that these trials validated an average urea cost saving of around $100 per hectare for the farmer. That is already more concrete and more demanding than a soft statement of “potential.”

But the other side has to be held at the same time. In its own comparison table against competing products, Grace presents Maoz at a use cost of around $70 per hectare in corn, plus starter urea at up to 50% of the normal amount. Against that, it says Corteva sells UTRISHA N at about $20 to $30 per hectare as part of a bundling strategy. So even if the agronomic proof improves materially, the commercial fight will still be decided not only by whether the product works, but by whether the economics for both the farmer and the distributor are strong enough against much larger competitors.

Sinova opened as an opportunity and closed as a warning

Trigger three: the company entered 2025 with a memorandum of understanding with Sinova group, a Brazilian player with commercial access to the agricultural market, to run broad corn field trials. In practice, only 16 trials were carried out in the safrinha season versus an original plan of 25, and most of them used full nitrogen because of farmers’ technical limitations. In other words, the exact stage that was supposed to push the story from controlled proof to commercial field validation ended up with a weaker protocol.

The more important part came in September 2025. The company announced the termination of its commercial ties with Sinova, among other reasons after identifying competitive activity by UPL, a Sinova stakeholder, which launched a competing product called Nuvita, and also after personnel changes that hurt the ability to monitor the trials. That is a material warning signal. It says the barrier on the way to market is not only scientific. It is also institutional. Even when there is a local partner, its interests do not necessarily line up with Grace’s.

GAPES and Mexico opened doors, but not yet the top line

Trigger four: after moving away from Sinova, Grace shifted toward independently controlled proof and third-party validation through five research stations in Brazil. In October 2025 it received final results from seven trials and simultaneously presented a 100-hectare commercial observation. In the GAPES benchmarking work, Maoz combined with 90 nitrogen units outperformed 120 nitrogen units without the product, and GAPES issued a formal recommendation for growers to begin commercial use in the next season. In January 2026 a new agreement with GAPES was already signed for another trial set, including 100 to 200 semi-commercial hectares between February and August 2026.

Trigger five: the Mexico story is similar, but it still has not reached cash either. Trials in corn and barley were conducted during 2025, but unusual weather delayed the harvest and prevented full quantitative readout. Even so, on 9 March 2026 the district administration selected Maoz for a multi-year program on around 1,000 hectares, and the company writes that it is in advanced negotiations to ship the product. That is a positive signal. It is still not a sale.

Africa already sounds large, but it is still not binding

In September 2025 Grace signed a non-binding memorandum of understanding for a Maoz Bio 5 sale in Africa in an estimated amount of $2 million to $5 million, and by December 2025 it was already talking about two African parties and two similar transactions worth several million dollars. But in the very same section the company says explicitly that the Africa process carries high uncertainty and that it is difficult to assess whether the deals will close and on what terms. Africa therefore widens the option set. It does not yet improve certainty for 2026.

Efficiency, Profitability And Competition

2025 was not a profitability year. It was a cost-cutting year. That distinction matters. Because there was no revenue at all, the improvement in the loss cannot be read as proof of better business economics. It has to be read as proof that the company managed to cut hard.

This chart sharpens what is easy to miss. About 73% of 2025 operating expenses sat in selling, general and administrative expense, while only NIS 648 thousand, about one quarter of the operating cost base, sat in R&D. That is not the expense profile of a company about to scale commercialization. It is the expense profile of a very small public company fighting to keep its skeleton alive.

The improvement in the P&L is real, but the quality of it is just as clear: revenue disappeared entirely, expenses came down, and the operating loss improved to NIS 2.467 million from NIS 2.793 million. There is no revenue engine here. There is a survival engine. Finance expense also moved back to a net expense of NIS 80 thousand, among other things because of interest on government-grant liabilities, after a small finance gain in 2024.

The saving also came from a softer organizational core

The cuts did not stop at the income statement lines. At the end of 2024 the company had 4 employees and contractors combined. At the end of 2025 it had only 2, one in management and one service contractor, and that remained the count near the report date. The filing says there is no dependence on any one employee, but in practice this is an extremely thin organization. That means any regulatory, trial or commercial delay weighs not only on growth but on the company’s ability to hold pace at all.

Farmer economics still have to pass through channel economics

The company wants to work through distributors and international partners, not to sell directly to the farmer. That means the economic question is not only whether Maoz saves nitrogen, but whether it gives both the distributor and the farmer a compelling profit model. In Brazil, in a market where BASF, Bayer, Syngenta, Corteva, FMC, UPL and Nufarm all operate, Grace has still not proved a route to market. That is more important than any one trial, because without a distributor or a commercial partner even good agronomic data stays just that, good agronomic data.

Cash Flow, Debt And Capital Structure

The framing has to be explicit here. In Grace’s case there is no point in talking about normalized or maintenance cash generation. There is no recurring cash-generating business yet. The relevant frame is all-in cash flexibility: how much cash is actually left after the period’s real cash uses.

In 2025 the company used NIS 1.789 million in operating activities, had almost no meaningful investment activity, and raised NIS 1.383 million through financing activity. At the end of the year it had NIS 474 thousand of cash and another NIS 101 thousand of deposits. In full cash terms, even after equity raises and warrant exercises, Grace finished the year with almost no real cushion.

The picture becomes even clearer when equity is considered. As of 31 December 2025 the company had an equity deficit of NIS 203 thousand. On top of that there was NIS 390 thousand of government-grant liability, NIS 481 thousand of accrued and other payables, and within that amount NIS 227 thousand of provision linked to the former-employees mediation arrangement. This is not classical bank debt, but it is a clear reminder that real available cash is tighter than the headline cash line alone suggests.

2025 was financed not only by placements, but also by waivers

This is one of the most important lines in the filing. The company reduced cash burn partly through an abnormal compensation structure. In 2025 it recognized NIS 481 thousand as an equity benefit because CEO Moris Zilkha and COO Yossi Raveh were effectively paid minimum wage rather than market terms. In parallel, additional directors signed waivers in July 2025 that reduced their compensation to the regulatory minimum through year-end, and part of the waiver structure remains in place through 30 June 2026.

The economic meaning is straightforward. Part of the improvement in cash burn did not come only from running fewer trials or paying ordinary lower salaries. It also came from the fact that the company has been living for a prolonged period on a highly unusual compensation framework. That is legitimate as a survival tool. It is simply not a basis from which to conclude that the company is already stabilized.

The January 2026 raise bought time, not a solution

After the balance-sheet date the company approved and completed another equity raise of NIS 610 thousand from five investors, together with 34,897 shares and 34,897 warrants. In addition, before year-end it had already received NIS 120 thousand from the exercise of 8,361 warrants, with the shares themselves issued in January 2026. That means the company did not enter 2026 with an empty cash box, but it also did not enter 2026 with a clean financing position.

If one combines the NIS 474 thousand of cash, NIS 101 thousand of deposits and the January 2026 raise, the result is a visible cushion, but still a small one relative to the 2025 burn rate. There is no contradiction between that and the going-concern note. If anything, that is exactly the explanation for it. Even after late-2025 and early-2026 funding, the company still has not built a structure that lets it reach commercialization without thinking constantly about the next round.

Not all the value would sit fully with public shareholders anyway

The company holds only 85% of Grace Technologies. Indofil owns the other 15%, and beyond that it still has certain board and approval rights so long as its stake stays above 10%. The report also says explicitly that since 2021 Grace Breeding has been funding the subsidiary while Indofil has not transferred its share of the funding, and that the company is in discussions to have it complete its share or be diluted accordingly. This matters because even if Maoz succeeds, the path from value creation in the operating activity to value that is fully accessible at the listed-company layer is not entirely frictionless.

Outlook

Before getting into the details, four findings matter most:

• First: 2025 solved much more of the agronomic question around Maoz, but not the first-customer question.
• Second: the company can no longer lean on the argument of “just a few more trials.” It already has enough trial evidence for the market to demand a move toward commercial proof.
• Third: Brazil remains the anchor, but the route has changed: less of an existing distributor path, more independent validation, and more reliance on GAPES and semi-commercial proof in 2026.
• Fourth: funding remains part of the thesis itself, not just background noise. Without money, good field data will still not convert into an order.

2026 looks like a commercial-proof year

This is not a breakout year, because the company itself says there is still no certainty on timing, scale or even the realization of commercialization. But it is also no longer just another ordinary R&D year. Grace enters 2026 with GAPES, with a route in Mexico, with Africa discussions, and with stronger Brazil results. That means 2026 will be judged less on whether another positive trial headline appears and more on three harder questions:

1. Does one of the routes become a binding order.
2. Can the company fund itself to that point without another heavy dilution step.
3. Do the economics of the product hold up against large incumbents under normal commercial conditions.

What has to happen in Brazil

Brazil remains the core market. The company has licensing there, results there, and a research-support route through GAIA. It also notes that during September 2025 it began testing different doses in soy, with results expected in March 2026. If soy works, the implication could be meaningful because it would improve the product’s position inside a soy-corn crop cycle. But even here the market will look less for another “good result” headline and more for the question of who actually pays.

What has to happen outside Brazil

Mexico can become a second proof route if the 1,000-hectare program really advances. Africa can become a material event if the $2 million to $5 million negotiation turns into an agreement. But for now both routes still sit outside revenue and outside backlog. They matter as upside to the thesis, not as a replacement for Brazil.

What could break the story

Two things stand out. The first is money. If the company has to go back to the market before it shows a first order or a meaningful distributor commitment, even good field results can be swallowed by dilution fear. The second is customer economics. If the real economics for the farmer or distributor are not clearly superior enough against UTRISHA N or other solutions, Maoz’s biological edge will not be enough on its own.

Risks

The first risk is clear and immediate funding risk. The company depends on outside funding, equity is negative, the auditor included a going-concern emphasis, and management itself says that without more financing only a few months of activity remain. This is not a tail risk. It is the main risk.

The second risk is commercialization risk. The filing says plainly that the company still has no experience commercializing its products in target markets. That is not legal boilerplate. It is an accurate description of the current stage. Grace has largely proved efficacy. It has still not proved market entry.

The third risk is competitive and economic risk. The company itself identifies Corteva as the main competitor and notes that bundling lets it price aggressively. Grace therefore does not need only a good product. It needs a channel capable of competing against much deeper pockets.

The fourth risk is an extremely thin organization. The filing says there is no formal dependence on any one employee. In practice, with only two people plus one service contractor, there is very little room for errors. Any delay or departure becomes an event very quickly.

The fifth risk is structural. Indofil still sits with 15% of the subsidiary and certain rights, even though it has not participated in funding since 2021. That does not eliminate Grace’s control, but it does add friction between technological success and value that flows cleanly to listed-company shareholders.

Conclusions

Grace Breeding ends 2025 as a company with a more mature product, but not as a more mature company. The Brazil proof, the GAPES recommendation and the Mexico opening all mean that the question of whether Maoz works looks much less open than before. On the other hand, the question of whether Grace can turn that proof into a funded commercial route is still very open. That is the main bottleneck, and it is also what will determine market interpretation over the short and medium term.

Current thesis: 2025 moved Grace from an experiment company to a proof company, but still not to a commercialization company.

What changed: the company no longer leans on several open formulations and several development directions. It compressed the story into one product, Maoz Bio 5, with stronger Brazil proof, a GAPES recommendation, and open doors in Mexico and Africa. At the same time, in the financial statements it remained without revenue, without backlog and with a going-concern note.

The counter-thesis: one can argue that this reading is still too harsh, because very few Israeli agtech names reach a point where they already have licensing in Brazil, strong field results, a recommendation from a body such as GAPES and an opening into a 1,000-hectare route in Mexico. If one of these routes becomes a paying order in 2026, the picture could change quickly.

What could change the market reading in the short to medium term: a first binding order, a distributor with real economic commitment, or a financing round that extends runway without wiping out existing shareholders. What would weigh on the reading is another full season of trials without a sale, or a quick return to the capital market before commercial proof.

Why this matters: in biotech and agtech it is notoriously hard to separate a good technology from a good business. Grace is now approaching the exact point where that difference gets exposed. If it crosses into commercial proof, the whole story changes. If it does not, 2025 will remain mainly a year of successful trials inside a weak financial wrapper.

What must happen over the next 2 to 4 quarters: GAPES or Mexico have to turn into a paid commercial route, the company has to build a firmer financing base, and the commercial path has to show that both the farmer economics and the distribution economics can hold against competition.